Losartan Potassium
Product Images NDC 53217-337

6 FDA label images from Aidarex Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 53217-337). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Losartan Pot 50mg 1)

Chemical Structure (Losartan Pot 50mg 1)
Chemical structure of Losartan Potassium, showing its molecular arrangement including aromatic rings, chlorine atom, hydroxymethyl group, and potassium ion.*
FDA Label Image

Figure 1 (Losartan Pot 50mg 2)

Figure 1 (Losartan Pot 50mg 2)
A line graph comparing the percentage of patients with primary endpoint events over study months between Atenolol and Losartan Potassium. The graph shows Atenolol with a dotted line and Losartan Potassium with a solid line, indicating lower events for Losartan Potassium. Annotations include an adjusted risk reduction of 13% with a p-value of 0.021.*
FDA Label Image

Figure 2 (Losartan Pot 50mg 3)

Figure 2 (Losartan Pot 50mg 3)
A line graph comparing the percentage of patients with fatal or non-fatal stroke over a 66-month study period for Losartan Potassium and Atenolol. The graph shows lower stroke incidence in patients treated with Losartan Potassium, with an adjusted risk reduction of 25% (p=0.001).*
FDA Label Image

Figure 3 (Losartan Pot 50mg 4)

Figure 3 (Losartan Pot 50mg 4)
A forest plot figure titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium and Atenolol. It presents hazard ratios with 95% confidence intervals for primary composite events and stroke (fatal/non-fatal) across subgroups including age, gender, race, isolated systolic hypertension (ISH), diabetes, and history of cardiovascular disease (CVD). Event rates for both treatments and numbers of patients are shown, with symbols proportional to sample size.*
FDA Label Image

Figure 4 (Losartan Pot 50mg 5)

Figure 4 (Losartan Pot 50mg 5)
A line graph comparing the percentage of patients with an event over 48 months between Losartan Potassium and Placebo. The x-axis represents time in months, and the y-axis shows the percentage of patients with an event. The graph indicates a risk reduction of 16.1% with Losartan Potassium compared to Placebo, with a p-value of 0.022.*
FDA Label Image

53217-0337_losartan-pot_50mg (Losartan Pot 50mg 6)

53217-0337_losartan-pot_50mg (Losartan Pot 50mg 6)
Losartan Potassium USP 50 mg tablet label, showing a package of 30 film-coated tablets. The label indicates the generic ingredient as losartan potassium with a dosage strength of 50 mg per tablet. It is produced by Zhejiang Huahai Pharmaceutical Co., Ltd. in China and labeled by Aidarex Pharmaceuticals LLC. The label includes the NDC 53217-0337-30 and other identifiers such as lot, RX number, and INS code.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.